SI2953977T1 - Imunokontrastno sredstvo za uporabo pri terapiji s konjugatom protitelo-zdravilo - Google Patents
Imunokontrastno sredstvo za uporabo pri terapiji s konjugatom protitelo-zdravilo Download PDFInfo
- Publication number
- SI2953977T1 SI2953977T1 SI201430556T SI201430556T SI2953977T1 SI 2953977 T1 SI2953977 T1 SI 2953977T1 SI 201430556 T SI201430556 T SI 201430556T SI 201430556 T SI201430556 T SI 201430556T SI 2953977 T1 SI2953977 T1 SI 2953977T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibody
- sequence
- seq
- immunoglobulin
- binding protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
- Imunokontrastno sredstvo za uporabo pri terapiji s konjugatom protitelo-zdravilo Patentni zahtevki1. Protitelesu podoben vezni protein, ki specifično veže MUC 1 -sialoglikotop povezan s tumorjem CA6, značilen po tem, da protitelesu podoben vezni protein vsebuje dva polipeptida, ki vsebujeta strukturi, ki jih predstavljata spodnji formuli (I) in (II): Vli-L,-VL2-Cl [I] Vh1-L2-Vh2-Chi [II] kjer: Vu predstavlja variabilno domeno lahke verige imunoglobulina, ki izhaja iz protitelesa DS6; V12 je variabilna domena lahke verige imunoglobulina, ki izhaja iz protitelesa DS6; Vhi je variabilna domena težke verige imunoglobulina, ki izhaja iz protitelesa DS6; Vh2 je variabilna domena težke verige imunoglobulina, ki izhaja iz protitelesa DS6; Cl je konstantna domena lahke verige imunoglobulina, kot je konstantna domena lahke verige imunoglobulina humane IGKC; Chi je konstantna domena težke verige imunoglobulina Cm, kot je konstantna domena težke verige imunoglobulina Chi; Li in L2 sta aminokislinska linkerja; in kjer polipeptidi s formulo I in polipeptidi s formulo II tvorijo bivalenten monospecifičen tandem imunoglobulin protitelesu podoben vezni protein; kjer polipeptid s formulo [I] vsebuje zaporedje, kije vsaj 80% enako z zaporedjem SEQ ID No: 1 in polipeptid s formulo II vsebuje zaporedje, kije vsaj 80% enako z zaporedjem SEQ ID No: 7.
- 2. Protitelesu podoben vezni protein po zahtevku 1, kjer sta Vli in Vl2 definirana z zaporedjem SEQ ID NO: 2; in sta VHi in Vh2 definirana z zaporedjem SEQ ID NO: 8.
- 3. Protitelesu podoben vezni protein po zahtevku 1 ali zahtevku 2, kjer Li predstavlja GGGGS ali GGGGSGGGGS (SEQ ID NO: 3).
- 4. Protitelesu podoben vezni protein po kateremkoli zahtevku od 1 do 3, kjer L2 predstavlja GGGGS ali GGGGSGGGGS (SEQ ID NO: 3).
- 5. Protitelesu podoben vezni protein po kateremkoli zahtevku od 1 do 4, kjer polipeptid s formulo [I] vsebuje zaporedje amino kislin SEQ ID NO: 1.
- 6. Protitelesu podoben vezni protein po kateremkoli zahtevku od 1 do 5, kjer the polipeptid s formulo [II] vsebuje zaporedje amino kislin SEQ ID NO: 7.
- 7. Protitelesu podoben vezni protein po kateremkoli zahtevku od 1 do 6, ki nadalje vsebuje vsaj radioaktivni označevalec, sredstvo za prikazovanje, terapevtsko sredstvo ali diagnostično sredstvo.
- 8. Protitelesu podoben vezni protein po zahtevku 7, kjer je radioaktivni označevalec, sredstvo za prikazovanje, terapevtsko sredstvo ali diagnostično sredstvo 110In,11'in, 177Lu, 18F, 52Fe, 62Cu, MCu, 67Cu, 67Ga, 68Ga, 86Y, 90Y, 89Zr, 94Tc, 94Tc, "mTc, 1201, 1231,124I, ‘25I, '3,1, 154-158Gd, 32P, "C, 13N, l50,186Re, l88Re,5‘Mn, 52mMn, 55Co,72As, 75Br, 76Br, 82mRb, ali 83Sr.
- 9. Protitelesu podoben vezni protein po zahtevku 7 ali 8, kjer radioaktivni označevalec, sredstvo za prikazovanje, terapevtsko sredstvo ali diagnostično sredstvo vsebuje eno ali več sredstev za prikazovalno platformo, izbrano iz skupine, ki vsebuje slikanje z magnetno resonanco (MRI); pozitronsko emisijsko tomografijo (PET); enofotonsko emisijsko tomografijo (SPECT); optično slikanje, računalniško tomografijo (CT); ultrazvok, rentgensko in fotoakustično slikanje.
- 10. Izolirana molekula nukleinske kisline, ki kodira polipeptide s formulo [I] in [II] protitelesu podobnega veznega proteina, kot je opisan v kateremkoli zahtevku od 1 do 6.
- 11. Izolirana molekula nukleinske kisline po zahtevku 10, kjer molekula nukleinske kisline vsebuje nukleotidno zaporedje SEQ ID NO: 5 ali SEQ ID NO: 10.
- 12. Ekspresijski vektor, ki vsebuje molekulo nukleinske kisline po zahtevku 10 ali 11.
- 13. Izolirana gostiteljska celica, ki vsebuje molekulo nukleinske kisline po zahtevku 10 ali 11, ali ekspresijski vektor po zahtevku 12.
- 14. Postopek izdelave protitelesu podobnega veznega proteina, ki specifično veže MUCl-sialoglikotop povezan s tumorjem CA6, ki obsega izražanje v celici ene ali več nukleinskih kislin, ki kodirajo polipeptide, ki imajo strukture, ki jih predstavljata spodnji formuli (I) in (II): VL.-L.-VL2-CL [I] Vh1-L2-Vh2-Chi [II] kjer: Vli predstavlja variabilno domeno lahke verige imunoglobulina, ki izhaja iz protitelesa DS6; Vl2 je variabilna domena lahke verige imunoglobulina, ki izhaja iz protitelesa DS6; VH1 je variabilna domena težke verige imunoglobulina, ki izhaja iz protitelesa DS6; Vh2 je variabilna domena težke verige imunoglobulina, ki izhaja iz protitelesa DS6; Cl je konstantna domena lahke verige imunoglobulina, kot je konstantna domena lahke verige imunoglobulina humane IGKC; Chi je konstantna domena težke verige imunoglobulina Cm, kot je konstantna domena težke verige imunoglobulina Chi; Li in L2 sta aminokislinska linkeija; in kjer polipeptidi s formulo I in polipeptidi s formulo II tvorijo bivalenten monospecifičen tandem imunoglobulin protitelesu podoben vezni protein; in kjer polipeptid s formulo [I] vsebuje zaporedje, kije vsaj 80% enako z zaporedjem SEQ ID No: 1 in polipeptid s formulo [II] vsebuje zaporedje, ki je vsaj 80% enako z zaporedjem SEQ ID No: 7
- 15. Postopek po zahtevku 14, kjer sta Vli in Vl2 definirana z zaporedjem SEQ ID NO: 2; in sta Vm in Vh2 definirana z zaporedjem SEQ ID NO: 8.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361761190P | 2013-02-05 | 2013-02-05 | |
| EP14305082 | 2014-01-21 | ||
| EP14717073.2A EP2953977B1 (en) | 2013-02-05 | 2014-02-05 | Immuno imaging agent for use with antibody-drug conjugate therapy |
| PCT/IB2014/000279 WO2014122529A1 (en) | 2013-02-05 | 2014-02-05 | Immuno imaging agent for use with antibody-drug conjugate therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2953977T1 true SI2953977T1 (sl) | 2018-02-28 |
Family
ID=50031282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430556T SI2953977T1 (sl) | 2013-02-05 | 2014-02-05 | Imunokontrastno sredstvo za uporabo pri terapiji s konjugatom protitelo-zdravilo |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2953977B1 (sl) |
| JP (1) | JP6605331B2 (sl) |
| KR (1) | KR20150113197A (sl) |
| CN (1) | CN105229034B (sl) |
| AU (1) | AU2014213687B2 (sl) |
| CA (1) | CA2900154A1 (sl) |
| DK (1) | DK2953977T3 (sl) |
| ES (1) | ES2657053T3 (sl) |
| HU (1) | HUE037909T2 (sl) |
| LT (1) | LT2953977T (sl) |
| MX (1) | MX2015010145A (sl) |
| PL (1) | PL2953977T3 (sl) |
| PT (1) | PT2953977T (sl) |
| RU (1) | RU2015137858A (sl) |
| SG (2) | SG11201506054XA (sl) |
| SI (1) | SI2953977T1 (sl) |
| WO (1) | WO2014122529A1 (sl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44381A (fr) * | 2015-06-15 | 2019-01-23 | Numab Innovation Ag | Format d'anticorps hétérodimères multispécifiques |
| CN110124057B (zh) * | 2019-06-06 | 2022-04-19 | 天津医科大学总医院 | 一种包含谷氨酰胺修饰的环糊精的抗肿瘤药物或药物载体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294904A1 (en) * | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| JP2007503202A (ja) | 2003-07-21 | 2007-02-22 | イミュノジェン・インコーポレーテッド | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2009504193A (ja) * | 2005-08-22 | 2009-02-05 | イミュノジェン・インコーポレーテッド | Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法 |
| GB0822001D0 (en) * | 2008-12-02 | 2009-01-07 | Glaxosmithkline Biolog Sa | Vaccine |
| EP2473524A4 (en) * | 2009-09-01 | 2013-05-22 | Abbott Lab | IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE |
| GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
-
2014
- 2014-02-05 PL PL14717073T patent/PL2953977T3/pl unknown
- 2014-02-05 SG SG11201506054XA patent/SG11201506054XA/en unknown
- 2014-02-05 RU RU2015137858A patent/RU2015137858A/ru not_active Application Discontinuation
- 2014-02-05 LT LTEP14717073.2T patent/LT2953977T/lt unknown
- 2014-02-05 AU AU2014213687A patent/AU2014213687B2/en not_active Ceased
- 2014-02-05 EP EP14717073.2A patent/EP2953977B1/en active Active
- 2014-02-05 SI SI201430556T patent/SI2953977T1/sl unknown
- 2014-02-05 MX MX2015010145A patent/MX2015010145A/es unknown
- 2014-02-05 JP JP2015555820A patent/JP6605331B2/ja active Active
- 2014-02-05 CN CN201480018589.6A patent/CN105229034B/zh active Active
- 2014-02-05 KR KR1020157023998A patent/KR20150113197A/ko not_active Application Discontinuation
- 2014-02-05 CA CA2900154A patent/CA2900154A1/en not_active Abandoned
- 2014-02-05 SG SG10201707391QA patent/SG10201707391QA/en unknown
- 2014-02-05 PT PT147170732T patent/PT2953977T/pt unknown
- 2014-02-05 HU HUE14717073A patent/HUE037909T2/hu unknown
- 2014-02-05 WO PCT/IB2014/000279 patent/WO2014122529A1/en active Application Filing
- 2014-02-05 DK DK14717073.2T patent/DK2953977T3/en active
- 2014-02-05 ES ES14717073.2T patent/ES2657053T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014213687B2 (en) | 2018-12-06 |
| WO2014122529A1 (en) | 2014-08-14 |
| DK2953977T3 (en) | 2018-01-22 |
| LT2953977T (lt) | 2018-02-12 |
| CN105229034A (zh) | 2016-01-06 |
| PT2953977T (pt) | 2018-01-29 |
| RU2015137858A (ru) | 2017-03-13 |
| PL2953977T3 (pl) | 2018-04-30 |
| CA2900154A1 (en) | 2014-08-14 |
| HUE037909T2 (hu) | 2018-09-28 |
| KR20150113197A (ko) | 2015-10-07 |
| JP6605331B2 (ja) | 2019-11-13 |
| JP2016509606A (ja) | 2016-03-31 |
| EP2953977B1 (en) | 2017-10-25 |
| SG10201707391QA (en) | 2017-10-30 |
| ES2657053T3 (es) | 2018-03-01 |
| SG11201506054XA (en) | 2015-08-28 |
| MX2015010145A (es) | 2016-05-31 |
| AU2014213687A1 (en) | 2015-08-20 |
| CN105229034B (zh) | 2019-12-10 |
| EP2953977A1 (en) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Massa et al. | Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging | |
| Olafsen et al. | Antibody vectors for imaging | |
| Kijanka et al. | Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery | |
| KR102353885B1 (ko) | Cd８에의 항원 결합 구조체들 | |
| JP7026613B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| Pruszynski et al. | Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody | |
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| Kobayashi et al. | Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology | |
| JP2018527919A5 (sl) | ||
| JP2017529067A5 (sl) | ||
| JP2016511254A5 (sl) | ||
| JP2013512920A5 (sl) | ||
| JP2015505665A5 (sl) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2017522886A5 (sl) | ||
| Rios et al. | Immuno-PET imaging and pharmacokinetics of an anti-CEA scFv-based trimerbody and its monomeric counterpart in human gastric carcinoma-bearing mice | |
| Steiner et al. | Tumor-targeting antibody–anticalin fusion proteins for in vivo pretargeting applications | |
| JP2014515600A5 (sl) | ||
| JP2018532689A5 (sl) | ||
| SI2953977T1 (sl) | Imunokontrastno sredstvo za uporabo pri terapiji s konjugatom protitelo-zdravilo | |
| US9989524B2 (en) | Immuno imaging agent for use with antibody-drug conjugate therapy | |
| HRP20180058T1 (hr) | Imunološko sredstvo za snimanje za uporabu s terapijom konjugatom protutijelo-lijek | |
| WO2016014839A9 (en) | Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72) | |
| CA3208566A1 (en) | Antibodies to igf2r and methods |